HomeNRSNW • NASDAQ
add
NeuroSense Therapeutics
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 2.99M | -17.77% |
Net income | -5.40M | -38.96% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | -2.99M | 17.85% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 735.00K | -83.34% |
Total assets | 1.45M | -72.90% |
Total liabilities | 8.44M | 245.01% |
Total equity | -6.99M | — |
Shares outstanding | 15.58M | — |
Price to book | -0.33 | — |
Return on assets | -323.26% | — |
Return on capital | 174.99% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Net income | -5.40M | -38.96% |
Cash from operations | — | — |
Cash from investing | — | — |
Cash from financing | — | — |
Net change in cash | — | — |
Free cash flow | — | — |
About
Founded
2017
Website
Employees
18
